{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T19:57:37Z","timestamp":1785700657747,"version":"3.56.0"},"reference-count":12,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Rituximab, an anti-CD20 monoclonal antibody used in B-cell malignancies, is associated with infusion-related reactions (IRRs) during the initial infusion. Standard premedication includes acetaminophen, corticosteroids, and a histamine-1 (H1) antagonist, typically diphenhydramine. Second-generation H1 antagonists offer similar efficacy with less sedation. Some institutions also incorporate histamine-2 (H2) antagonists despite limited supporting evidence.\u202fThis study evaluated whether dual H1\/H2 antagonist premedication reduces IRRs compared with H1-antagonist monotherapy when given with standard premedication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study reviewed health records of adults with a hematologic malignancy who received their first rituximab infusion at Brown University Health system between January 1, 2022 and June 30, 2025. Patients received premedication with either an H1-antagonist alone or dual H1\/H2 receptor-antagonists with acetaminophen and a corticosteroid. The primary endpoint was IRR incidence during or within 24\u2005h of infusion initiation. Secondary endpoints included IRR severity, incidence of grade 3\u20134 IRRs across subgroups, and time to IRR onset.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 299 patients (mean age 65; 55% male), 62% had aggressive lymphoma, 28% indolent lymphoma, and 10% leukemia. Baseline features included bone marrow involvement (38%), bone disease (39%), advanced-stage nodal disease (54%), B symptoms (48%), and &gt;2 extranodal sites (28%). IRRs occurred in 38% of patients receiving dual H1\/H2 antagonist premedication versus 36.5% with H1-antagonist monotherapy, with no difference in grade 3\u20134 IRRs. Most IRRs occurred 30 to 60\u2005min after infusion initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Dual H1\/H2-antagonist premedication was not associated with differences in the incidence or severity of rituximab IRRs compared with H1-antagonist monotherapy in addition to standard premedication.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552261466574","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:39:51Z","timestamp":1785418791000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of H1 versus combined H1\/H2 antagonist premedication on incidence of rituximab infusion-related reaction: A retrospective cohort study"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6178-3560","authenticated-orcid":false,"given":"Ngan N","family":"Nguyen","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Rhode Island Hospital"},{"name":"Department of Pharmacy, University of Rhode Island College of Pharmacy, Kingston, RI, USA"},{"name":"Department of Pharmacy, Brown University Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah M","family":"Kisla","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Rhode Island Hospital"},{"name":"Department of Pharmacy, University of Rhode Island College of Pharmacy, Kingston, RI, USA"},{"name":"Department of Pharmacy, Brown University Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Sorial","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Dana Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin C","family":"Liauw","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Rhode Island Hospital"},{"name":"Department of Pharmacy, University of Rhode Island College of Pharmacy, Kingston, RI, USA"},{"name":"Department of Pharmacy, Brown University Health"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"e_1_3_2_2_2","volume-title":"Rituxan (package insert)","author":"Genentech Inc","year":"2012","unstructured":"Genentech Inc. Rituxan (package insert). South San Francisco, CA: Genentech Inc, 2012."},{"key":"e_1_3_2_3_2","volume-title":"Riabni (package insert)","author":"Amgen Inc","year":"2020","unstructured":"Amgen Inc. Riabni (package insert). Thousand Oaks, CA: Amgen Inc, 2020."},{"key":"e_1_3_2_4_2","volume-title":"Truxima (package insert)","author":"Celltrion Inc","year":"2018","unstructured":"Celltrion Inc. Truxima (package insert). North Wales, PA: Celltrion Inc, 2018."},{"key":"e_1_3_2_5_2","volume-title":"Ruxience (package insert)","author":"Pfizer Inc","year":"2019","unstructured":"Pfizer Inc. Ruxience (package insert). New York City, NY: Pfizer Inc, 2019."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.08.028"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-025-03990-6"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.e13508"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01999-x"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.e19148"},{"key":"e_1_3_2_11_2","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas. Version 3.2026 https:\/\/www.nccn.org (2026 accessed April 4 2026)."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32985"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03166.x"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261466574","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552261466574","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261466574","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T19:43:30Z","timestamp":1785699810000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552261466574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":12,"alternative-id":["10.1177\/10781552261466574"],"URL":"https:\/\/doi.org\/10.1177\/10781552261466574","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"article-number":"10781552261466574"}}